Tetraxetan

Tetraxetan

SCHEMBL2017956

O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1.O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1.O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.64
SLC6A9 P48067 1/20 0.47
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
STAT6 P42226 1/20 0.41
S1PR1 P21453 1/20 0.41
GAA P10253 1/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.38
CYP1A2 P05177 1/20 0.37
MAPK1 P28482 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173508 1.00 HSD17B10 (0.64) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
SCHEMBL321989 1.00 HSD17B10 (0.64) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
SCHEMBL3660521 1.00
SCHEMBL6848102 1.00 HSD17B10 (0.64) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
Tetraxetan SCHEMBL18018 1.00 HSD17B10 (0.64) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
SCHEMBL6744121 1.00 HSD17B10 (0.64) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
SCHEMBL3503521 1.00 HSD17B10 (0.64) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
Tetraxetan SCHEMBL2635294 1.00 HSD17B10 (0.64) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
Tetraxetan SCHEMBL23647851 0.97 HSD17B10 (0.61) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6
Tetraxetan SCHEMBL15766009 0.97 HSD17B10 (0.61) HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9284381-B2 Methods and reagents for preparing multifunctional probes THE GENERAL HOSPITAL CORPORATION (US) 2016-03-15 US disclosed
US-20130295640-A1 Methods and Reagents for Preparing Multifunctional Probes JOSEPHSON LEE (US) 2013-11-07 US disclosed
US-8546531-B2 Methods and reagents for preparing multifunctional probes THE GENERAL HOSPITAL CORPORATION (US) 2013-10-01 US disclosed
US-20110159566-A1 Methods and Reagents for Preparing Multifunctional Probes NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110159566-A1 Methods and Reagents for Preparing Multifunctional Probes LNPEP, MSN, PDAP1 HSD17B10 4026/4885SLC6A9 4710/4885ALDH1A1 3369/4885
US-20130295640-A1 Methods and Reagents for Preparing Multifunctional Probes LNPEP, PDAP1, MSN HSD17B10 4121/4885SLC6A9 4746/4885ALDH1A1 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.